AAO News Archive
- Deal struck to develop integrin antagonist treatment
- New low-add multifocal IOLs yield higher patient satisfaction
- Regeneron, Bayer to develop AMD combination therapy
- FDA approves wide-field imaging system for newborns
- Brain mapping may someday lead to vision-restoring therapies
- FDA warns of loose safety seals on eye drops
- Stem cells regrow human lens, corneal tissue
Find an Eye MD near you!
- Details
Allergan Plc. has purchased AqueSys and its minimally invasive soft shunt for glaucoma, XEN45
Read more: Allergan acquires minimally invasive glaucoma shunt
- Details
Avedro has resubmitted a new drug application for its riboflavin opthalmic solution/KXL system for corneal cross-linking (CXL).
Read more: Avedro resubmits FDA application for CXL treatment
- Details
Dr. Sam Masket developed an IOL to prevent negative dysphotopsia, the dark or grey arc-shaped shadow seen in the temporal field of vision following uncomplicated cataract surgery.
- Details
The first clinical trial of an extended-release formulation of travoprost shows it’s comparable to topical once-daily travoprost in patients with glaucoma.
- Details
Alcon reports that the U.S. FDA has approved its AcrySof IQ aspheric IOL with the UltraSert pre-loaded delivery system.
- Details
A complete work-up immediately following nonarteritic central retinal artery occlusion picks up undiagnosed cardiovascular risk factors in almost 80% of patients.
Read more: CRAO patients at high risk for undiagnosed cardiovascular risk factors